Bluechiip Limited Stock Market Press Releases and Company Profile
Bluechiip Displays OEM IVF Tracking Product at Major Trade Show in Helsinki
Bluechiip Displays OEM IVF Tracking Product at Major Trade Show in Helsinki

Sydney, July 7, 2016 AEST (ABN Newswire) - Bluechiip Limited (googlechartASX:BCT), a leader in the development of sample tracking technology for harsh environments, today announced the successful display of its tracking technology at the European Society of Human Reproductive Embryology (ESHRE) trade show in Helsinki, Finland. ESHRE's four-day trade show is the world's largest for assistive reproductive technologies (ART), attracting more than 10,000 attendees and hundreds of major vendors presenting new products and technologies for the in vitro fertilization market.

This is the first time one of our OEM partners has included Bluechiip's technology in a tradeshow exhibition: in this case a major Australian IVF device manufacturer included our tracking chip and associated hand-held tracking technology in their ART storage cassette.

Bluechiip CEO Andrew McLellan said the display represents a significant milestone in Bluechiip's OEM partner strategy. "The value to the company of our technology being shown in our OEM partners' products cannot be underestimated. We are now gaining traction as a real solution for industries that need tracking in harsh environments.

"This exhibition follows the development and supply agreement we executed with this partner in December 2015. We expect that the underlying products will launch in the market early in calendar year 2017."

New patent

Bluechiip also announces that it has filed a provisional patent, describing the use of Bluechiip tags in systems used to transport biological samples, titled "A system, method and device for transporting, handling and monitoring samples in a temperature-controlled storage environment". This provisional patent strengthens our position in the market and protects our unique technology that tracks identity and measures temperature at the sample level.

The new provisional patent adds an additional family of patents to our library. Bluechiip now has 24 granted and 6 pending patents across 9 patent families.

About Bluechiip Limited

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

 

https://twitter.com/bluechiip https://www.youtube.com/channel/UCaVcyO4O2oJ_9fLdMs6JIyQ https://www.linkedin.com/company/bluechiip-limited abnnewswire.com 


Contact

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 4) (Last 30 Days: 20) (Since Published: 1832)